$SBFM Biotech Investor QA with CFO of Sunshin
Post# of 99241
$SBFM Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB: SBFM)
Discussing its Lead Compound - Adva-27a for Aggressive Forms of Cancer
New York, New York - July 2, 2012 - Investorideas.com, an investor research portal specializing in sector
research including biotech and pharma stocks, issues an exclusive Q&A interview with Mr. Camille
Sebaaly, CFO of Sunshine Biopharma Inc. (OTCBB:SBFM). Sunshine Biopharma is a pharmaceutical
company focused on the research, development and commercialization of drugs for the treatment of
various forms of cancer. The Company’s lead compound, Adva-27a targets aggressive forms of cancer.
Mr. Sebaaly also shares insight on Roche’s (SIX: RO, ROG; OTCQX: RHHBY) Herceptin® cancer drug.
Interview:
Q: Investorideas.com staff
Can you give investors a brief background on your lead compound, Adva-27a, your proprietary
technology behind it and how it targets aggressive forms of cancer?
A: Mr. Camille Sebaaly, CFO
Adva-27a is a small molecule which we designed and synthesized de novo. Patents covering
Adva-27a and derivatives have been issued in the United States and Europe and are still
pending in other places around the world. Adva-27a was designed it to specifically target
multidrug resistant (or aggressive) types of cancer.
Q: Investorideas.com staff
The Company announced findings last week from the cytotoxicity study- can you give us
some brief hi-lights and the significance of the results?
A: Mr. Camille Sebaaly, CFO
Last week we announced the results of our most recent studies in which we found that Adva-
27a is remarkably capable of killing multidrug resistant small cell lung cancer. Small cell lung
cancer is perhaps the most aggressive primary cancer. Sadly, the prognosis for a freshly
diagnosed patient with small cell lung cancer is only a few months. As you know, we had
announced back in July of last year that Adva-27a also kills multidrug resistant breast cancer
cells. Similarly, the prognosis for multidrug resistant breast cancer patients is only a few
months. We are delighted at the opportunity to offer both of these patient groups hope through
our Adva-27a. As far we know, Adva-27a is the only drug anywhere in the world that can treat
these patients.
Q: Investorideas.com staff
Can you discuss briefly the pharmacokinetics studies results announced in May?
A: Mr. Camille Sebaaly, CFO
The pharmacokinetic parameters of Adva-27a which we announced in May were excellent.
Adva-27a has all the properties of a good pharmaceutical. For example, it reaches a very high
initial plasma concentration, which means it starts working fast, and has an intermediates
plasma half-life implying that it does not linger in the blood stream to cause severe side-effects
and other complications.
Q: Investorideas.com staff
Can you give investors insight into the type of cancer Herceptin®, a drug marketed by Roche
(SIX: RO, ROG; OTCQX: RHHBY) (the world's largest biotech company) targets and where you
see Sunshine Biopharma filling the gap?
A: Mr. Camille Sebaaly, CFO
Herceptin® is an excellent drug and is very effective in treating Her2-Positive breast cancer
patients. However, only about 25% of the breast cancer patients are Her2-Positive. For the
remaining 75%, Herceptin® does not work. This is where our Adva-27a comes in. It is
interesting to note that Herceptin® sales are in excess of $5 billion a year.
About Sunshine Biopharma Inc. (OTCBB: SBFM)
www.sunshinebiopharma.com
SBFM Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com
(0)
(0)